NuCana NCNA Stock
NuCana Price Chart
NuCana NCNA Financial and Trading Overview
| NuCana stock price | 1.35 USD |
| Previous Close | 1.28 USD |
| Open | 1.29 USD |
| Bid | 0.96 USD x 200 |
| Ask | 1.66 USD x 200 |
| Day's Range | 1.28 - 1.34 USD |
| 52 Week Range | 1.21 - 13 USD |
| Volume | 82.73K USD |
| Avg. Volume | 48.11K USD |
| Market Cap | 5.54M USD |
| Beta (5Y Monthly) | 2.236 |
| PE Ratio (TTM) | 0.010714574 |
| EPS (TTM) | 132.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NCNA Valuation Measures
| Enterprise Value | -15521805 USD |
| Trailing P/E | 0.010714574 |
| Forward P/E | -0.14103924 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.18767567 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.687 |
Trading Information
NuCana Stock Price History
| Beta (5Y Monthly) | 2.236 |
| 52-Week Change | -87.20% |
| S&P500 52-Week Change | 20.36% |
| 52 Week High | 13 USD |
| 52 Week Low | 1.21 USD |
| 50-Day Moving Average | 1.87 USD |
| 200-Day Moving Average | 2.84 USD |
NCNA Share Statistics
| Avg. Volume (3 month) | 48.11K USD |
| Avg. Daily Volume (10-Days) | 84.53K USD |
| Shares Outstanding | 4.16M |
| Float | 4.16M |
| Short Ratio | 2.46 |
| % Held by Insiders | 0.0020% |
| % Held by Institutions | 1.38% |
| Shares Short | 115.77K |
| Short % of Float | 2.77% |
| Short % of Shares Outstanding | 2.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:200 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -72.79% |
| Return on Equity (ttm) | -231.67% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -22592000 USD |
| Net Income Avi to Common (ttm) | -30745000 USD |
| Diluted EPS (ttm) | 124.13 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 21.53M USD |
| Total Cash Per Share (mrq) | 5.17 USD |
| Total Debt (mrq) | 680K USD |
| Total Debt/Equity (mrq) | 3.04 USD |
| Current Ratio (mrq) | 5.482 |
| Book Value Per Share (mrq) | 7.086694 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7540000 USD |
| Levered Free Cash Flow (ttm) | -3203750 USD |
Profile of NuCana
| Country | United States |
| State | N/A |
| City | Edinburgh |
| Address | 3 Lochside Way |
| ZIP | EH12 9DT |
| Phone | 44 13 1357 1111 |
| Website | https://www.nucana.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 10 |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Q&A For NuCana Stock
What is a current NCNA stock price?
NuCana NCNA stock price today per share is 1.35 USD.
How to purchase NuCana stock?
You can buy NCNA shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NuCana?
The stock symbol or ticker of NuCana is NCNA.
Which industry does the NuCana company belong to?
The NuCana industry is Biotechnology.
How many shares does NuCana have in circulation?
The max supply of NuCana shares is 4.16M.
What is NuCana Price to Earnings Ratio (PE Ratio)?
NuCana PE Ratio is 0.01022650 now.
What was NuCana earnings per share over the trailing 12 months (TTM)?
NuCana EPS is 132.01 USD over the trailing 12 months.
Which sector does the NuCana company belong to?
The NuCana sector is Healthcare.
NuCana NCNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26269.23 USD — |
+0.62
|
6.33B USD — | 26041.13 USD — | 26316.81 USD — | — - | 6.33B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12896.68 USD — |
+0.64
|
— — | 12785.35 USD — | 12920.04 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1251.97 USD — |
+0.86
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
- {{ link.label }} {{link}}